Investors will have the opportunity to contribute to the development towards an attractive exit scenario.

undefinedFor further discussion please contact Horst Lindhofer

Investment Opportunity

LINDIS Biotech offers a unique ‘high potential – low risk’ opportunity to investors:

  • Innovative product candidate targeting significant unmet medical needs in growth segments
  • Based on the validated Triomab® platform, of which the first candidate is already on the market
  • Unique mode of action offering significant advantages over existing treatments
  • Preclinical proof of concept established
  • Key service agreements for pre-/clinical support and GMP manufacturing in place
  • Proprietary IP rights for ektomun and secured freedom to operate
  • Short time-to-market expected (8 years from lab to market for the first Triomab® candidate)
  • Experienced development team
  • Dedicated infrastructure, know-how, tools and services at hand